|
1. Biologie
|
|
|
|
|
2.5 Etiologie - Gènes
|
|
|
|
3.1 Prévention - Tabac
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
|
|
5. Traitements
|
|
|
New Technique Predicts Gene Resistance to Cancer Treatments [Yale]
|
|
|
|
|
|
Using
a national database of tumor sequences along with tumor sequences from
previous Yale studies, the researchers created a promising evolutionary
framework with potential utility in prediction of pathways to resistance
to new targeted therapies as they become available.
|
|
|
|
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
|
5.12.10 Immunothérapies - Fusions et acquisitions
|
|
|
Merck inks $394M takeover of oncolytic virus play Viralytics [FierceBiotech]
|
|
|
|
|
|
Viralytics
is involved in three Cavatak-Keytruda combination trials. Merck was
already collaborating with Viralytics on one of the trials, which is
testing the cocktail in patients with bladder cancer and non-small cell
lung cancer (NSCLC). The other two phase 1 trials are targeting patients
with advanced melanoma and NSCLC.
|
|
|
|
|
|
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
Arcus Biosciences eyes $100M IPO [FierceBiotech]
|
|
|
|
|
|
AB928
and AB122 are both in phase 1 trials, which are expected to read out
this year. The former will enter a phase 1/2 study in the second
quarter, and a treatment combining the two is also on deck for phase
1/2.
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
5.6 ESMO
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.3 Associations/Fondations
|
|
|
|
6.6 Publications
|
|
|
ORCID Mandate Trial at Springer Nature [ORCID]
|
|
|
|
|
|
For
the 14 Nature-branded titles, the percentage of corresponding authors
on published papers providing an ORCID identifier grew over the course
of the trial from 37% to 96%. As a comparison, for Nature-branded titles
that did not take part in the trial this percentage increased from 26%
to 45%.
|
|
|
|
|
|
|